Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.

Yaura, Kazuma; Sakurai, Kanako; Niitsuma, Satsuki; Sato, Ryota; Takahashi, Kazuhiro; Arihara, Zenei

Yaura, Kazuma; Sakurai, Kanako; Niitsuma, Satsuki; Sato, Ryota; Takahashi, Kazuhiro; Arihara, Zenei.

Afiliação

Yaura K; Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.
Sakurai K; Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.
Niitsuma S; Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.
Sato R; Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.
Takahashi K; Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine.
Arihara Z; Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center.

Tohoku J Exp Med ; 254(4): 253-256, 2021 08.

Article em En | MEDLINE | ID: mdl-34373422

Assuntos

Diabetes Mellitus Tipo 1; Neoplasias Renais; Diabetes Mellitus Tipo 1/induzido quimicamente; Feminino; Humanos; Inibidores de Checkpoint Imunológico; Ipilimumab/efeitos adversos; Pessoa de Meia-Idade; Nivolumabe/efeitos adversos

Palavras-chave

diabetic ketoacidosis; fulminant type 1 diabetes mellitus; immune checkpoint inhibitor; ipilimumab; nivolumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Neoplasias Renais Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google